Page last updated: 2024-08-24

fluorodeoxyglucose f18 and 3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol

fluorodeoxyglucose f18 has been researched along with 3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Das, M; Dingemans, AC; Even, AJG; Lambin, P; Mottaghy, FM; Oellers, M; Reymen, B; Troost, EGC; van Elmpt, W; Wildberger, JE; Zegers, CML1

Trials

1 trial(s) available for fluorodeoxyglucose f18 and 3-fluoro-2-(4-((2-nitro-1h-imidazol-1-yl)methyl)-1h-1,2,3-triazol-1-yl)propan-1-ol

ArticleYear
Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:2

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Nitroimidazoles; Oxygen; Oxygen Consumption; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles

2016